|1||NCT02259621||Recruiting||Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC||
||Other / Industry||
||30||All||18 Years and older (Adult, Senior)||NCT02259621||J1414
|NA_00092076||September 2014||January 2023||January 2023||October 8, 2014||November 6, 2017||
|2||NCT01774409||Recruiting||Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer||
||2000||All||Child, Adult, Senior||NCT01774409||PROFILER
|PROFILER||February 2013||July 2020||July 2020||January 24, 2013||February 14, 2018||
† Study has passed its completion date and status has not been verified in more than two years.